Ultragenyx Pharmaceutical (RARE) Total Current Liabilities (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Total Current Liabilities of $325.0 million for Q1 2026, up 11.43% year-over-year from $291.7 million in Q1 2025, and down 15.36% on a QoQ basis from $384.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Total Current Liabilities data on file, last reported at $325.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 11.43% year-over-year to $325.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $325.0 million (up 11.43% YoY) and the FY2025 annual result came in at $384.0 million, up 11.63% from the prior year.
- Total Current Liabilities fell to $325.0 million in Q1 2026 per RARE's latest filing, from $384.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $384.0 million in Q4 2025 and bottomed at $167.2 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $272.9 million (2024), against an average of $273.8 million.
- The widest annual swing landed in 2022, when Total Current Liabilities soared 73.64%; it then climbed 7.36% in 2023.
- Tracing RARE's Total Current Liabilities over 5 years: stood at $261.2 million in 2022, then increased by 7.36% to $280.4 million in 2023, then advanced by 22.67% to $344.0 million in 2024, then climbed by 11.63% to $384.0 million in 2025, then slipped by 15.36% to $325.0 million in 2026.
- Per Business Quant, the three latest RARE Total Current Liabilities figures stand at $325.0 million (Q1 2026), $384.0 million (Q4 2025), and $340.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 325.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 325.00 Mn |
| Dec 31, 2025 | 384.00 Mn |
| Sep 30, 2025 | 340.02 Mn |
| Jun 30, 2025 | 293.24 Mn |
| Mar 31, 2025 | 291.67 Mn |
| Dec 31, 2024 | 344.00 Mn |
| Sep 30, 2024 | 285.01 Mn |
| Jun 30, 2024 | 272.87 Mn |
| Mar 31, 2024 | 245.58 Mn |
| Dec 31, 2023 | 280.44 Mn |
| Sep 30, 2023 | 253.98 Mn |
| Jun 30, 2023 | 244.38 Mn |
| Mar 31, 2023 | 218.18 Mn |
| Dec 31, 2022 | 261.21 Mn |
| Sep 30, 2022 | 227.36 Mn |
| Jun 30, 2022 | 220.64 Mn |
| Mar 31, 2022 | 167.23 Mn |
| Dec 31, 2021 | 181.37 Mn |
| Sep 30, 2021 | 135.93 Mn |
| Jun 30, 2021 | 127.07 Mn |
| Mar 31, 2021 | 127.04 Mn |
| Dec 31, 2020 | 189.61 Mn |
| Sep 30, 2020 | 201.19 Mn |
| Mar 31, 2020 | 196.86 Mn |
| Dec 31, 2019 | 103.30 Mn |
| Sep 30, 2019 | 90.31 Mn |
| Jun 30, 2019 | 75.01 Mn |
| Mar 31, 2019 | 66.88 Mn |
| Dec 31, 2018 | 74.73 Mn |
| Sep 30, 2018 | 66.68 Mn |
| Jun 30, 2018 | 66.05 Mn |
| Mar 31, 2018 | 57.58 Mn |
| Dec 31, 2017 | 71.01 Mn |
| Sep 30, 2017 | 64.26 Mn |
| Jun 30, 2017 | 62.68 Mn |
| Mar 31, 2017 | 51.76 Mn |
| Dec 31, 2016 | 60.26 Mn |
| Sep 30, 2016 | 50.43 Mn |
| Jun 30, 2016 | 31.98 Mn |
| Mar 31, 2016 | 29.88 Mn |
| Dec 31, 2015 | 27.92 Mn |
| Sep 30, 2015 | 24.73 Mn |
| Jun 30, 2015 | 23.04 Mn |
| Mar 31, 2015 | 14.24 Mn |
| Dec 31, 2014 | 12.52 Mn |
| Sep 30, 2014 | 11.07 Mn |
| Jun 30, 2014 | 8.94 Mn |
| Mar 31, 2014 | 6.81 Mn |
| Dec 31, 2013 | 5.92 Mn |